Nautilus Biotechnology reports FY2023 net loss $63.7M; cash runway into H2 2026

Nautilus Biotechnology, Inc.

2023-FY EPS reported -$0.51

Net loss $63.7M for FY2023, compared to $57.9M in FY2022; operating expenses $76.2M, up 20% YoY.
Cash, equivalents and investments $264.1M as of Dec 31, 2023; expected runway into second half 2026.
FY2024 operating expense expected to grow ~25% vs 2023.
Platform launch (instruments, consumables, software) planned for 2025.
CEO Sujal Patel cited fiscal discipline and progress on proprietary proteome analysis platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nautilus Biotechnology, Inc. updated its Fiscal Year 2024 Outlook guidance (initiated).

Period: Fiscal Year 2024 Outlook
Guidance: initiated
Result: guidance update

Exact text from the filing

Fiscal Year 2024 Outlook • We expect full year operating expense to grow by approximately 25% relative to 2023 • We expect that cash and cash equivalents and investments of $264.1 million as of December 31, 2023 to provide a runway into the second half of 2026 • We expect to launch our platform, instruments, consumables, and software in 2025.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nautilus Biotechnology, Inc. reported the fiscal year ended December 31, 2023 results: net income $63.7 million.

Period: the fiscal year ended December 31, 2023
Net income: $63.7 million
Result: reported results

Exact text from the filing

Net loss was $63.7 million for the year ended December 31, 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.